Literature DB >> 16750726

Clinical outcomes of low-risk patients undergoing beating-heart surgery with or without pulmonary artery catheterization.

Fernando G Resano1, Emmanouil I Kapetanakis, Peter C Hill, Elizabeth Haile, Paul J Corso.   

Abstract

OBJECTIVE: For patients who undergo off-pump coronary artery bypass (OPCAB) surgery, pulmonary artery catheterization (PAC) has been proposed as a useful intraoperative monitoring tool. This study was designed to determine if the choice of PAC versus central venous pressure monitoring (CVP) had any effect on outcome after OPCAB. This study compared these 2 methods of hemodynamic monitoring in low-risk patients undergoing beating-heart surgery via a median sternotomy and evaluated their effect on morbidity and in-hospital mortality.
DESIGN: Retrospective database and medical record review.
SETTING: Tertiary care teaching hospital. PARTICIPANTS: Low-risk patients who had coronary revascularization via a median sternotomy on the beating heart.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: A population of 2,414 low-risk patients who had beating-heart coronary revascularization between January 2000 and December 2003 was reviewed. Most patients (1,671 or 69.2%) received a PAC, whereas 743 (30.8%) had CVP monitoring. Risk-adjusted logistic regression analyses were performed to investigate the effect of each technique on clinical outcomes. The groups were comparable in both baseline characteristics and Parsonett's mortality risk (1.5 +/- 0.9, p = 0.58). Univariate analysis failed to show a difference in operative mortality (p = 0.76), on-pump conversion rate for completion of aortocoronary bypasses (p = 0.82), postoperative low cardiac output (p = 0.10), or prolonged inotropic agent use (p = 0.22). Similarly, in the multivariate analysis, both groups had a similar rate of conversion to an on-pump procedure for completion of coronary artery grafting (p = 0.91), intraoperative intra-aortic balloon pump use (p = 0.69), low cardiac output state (p = 0.16), or in-hospital mortality (p = 0.51).
CONCLUSIONS: This single-institution, retrospective study suggests that in low-risk patients undergoing beating-heart surgery, CVP monitoring may be sufficient.

Entities:  

Mesh:

Year:  2006        PMID: 16750726     DOI: 10.1053/j.jvca.2006.01.017

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  6 in total

Review 1.  Newer methods of cardiac output monitoring.

Authors:  Yatin Mehta; Dheeraj Arora
Journal:  World J Cardiol       Date:  2014-09-26

2.  S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system.

Authors:  M Carl; A Alms; J Braun; A Dongas; J Erb; A Goetz; M Goepfert; W Gogarten; J Grosse; A R Heller; M Heringlake; M Kastrup; A Kroener; S A Loer; G Marggraf; A Markewitz; D Reuter; D V Schmitt; U Schirmer; C Wiesenack; B Zwissler; C Spies
Journal:  Ger Med Sci       Date:  2010-06-15

3.  Cardiac output assessed by invasive and minimally invasive techniques.

Authors:  Allison J Lee; Jennifer Hochman Cohn; J Sudharma Ranasinghe
Journal:  Anesthesiol Res Pract       Date:  2011-07-06

4.  Perioperative fluid therapy: a statement from the international Fluid Optimization Group.

Authors:  Lais Helena Camacho Navarro; Joshua A Bloomstone; Jose Otavio Costa Auler; Maxime Cannesson; Giorgio Della Rocca; Tong J Gan; Michael Kinsky; Sheldon Magder; Timothy E Miller; Monty Mythen; Azriel Perel; Daniel A Reuter; Michael R Pinsky; George C Kramer
Journal:  Perioper Med (Lond)       Date:  2015-04-10

5.  Use of pulmonary artery catheter in coronary artery bypass graft. Costs and long-term outcomes.

Authors:  Fei Xu; Qian Wang; Heng Zhang; Sipeng Chen; Hushan Ao
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

Review 6.  The Pulmonary Artery Catheter in the Perioperative Setting: Should It Still Be Used?

Authors:  Thomas Senoner; Corinna Velik-Salchner; Helmuth Tauber
Journal:  Diagnostics (Basel)       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.